Peptide History intermediate
History of Peptide Vaccines
The development of peptide-based vaccines from early epitope mapping to neoantigen approaches.
By Encyclopeptide Editorial | 1 min read
vaccine immunology history cancer
Overview
Peptide vaccine development began with the identification of T-cell epitopes in the 1980s and has advanced to personalized neoantigen vaccines.
Key Milestones
- 1980s: MHC-peptide binding characterized
- 1990s: First cancer peptide vaccine trials
- 1995: Melanoma antigen peptides identified
- 2000s: Multi-epitope vaccine designs
- 2010s: Neoantigen discovery pipelines
- 2020s: COVID-19 peptide vaccine candidates
- 2020s: Personalized neoantigen vaccines in trials
Impact
Peptide vaccines offer safety, specificity, and rapid design. Neoantigen approaches represent personalized immunotherapy for cancer patients.
References
- Source: ENCP Peptide Database
- Category: Peptide History
Test Your Knowledge
Reinforce what you learned about History of Peptide Vaccines with interactive quizzes on Wikipept.
Take a Quiz on Wikipept